We have located links that may give you full text access.
Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
Clinical Cancer Research 2020 October 24
PURPOSE: Thyroid disease is a frequent comorbidity in women with breast cancer (BC), and many require thyroid hormone(TH) replacement therapy(THRT). We postulated that THRT has a deleterious clinical effect mechanistically through hormonal interactions, nuclear receptor cross-talk and upregulation of high-risk BC genes.
EXPERIMENTAL DESIGN: Observational studies of lymph node-negative (LN-) BC patients (n= 820 and n=160) were performed to test interactions between THRT and clinical, histologic, outcome and treatment variables. Differences between the two cohorts include but are not limited to patient numbers, decades of treatment, duration of follow-up/treatment, tumor sizes, incidence, type and dose/regimen of anti-hormonal and/or chemotherapeutic agents. In vivo and vitro models, in silico databases and molecular methods were used to study interactions and define mechanisms underlying THRT effects.
RESULTS: THRT significantly and independently reduced disease-free and BC specific overall survival of only the steroid receptor (SR) positive (as compared to SR negative) node-negative patients in both long-term observational studies. SR+ LN- BC patients who received THRT and tamoxifen experienced the shortest survival of all treatment groups. A less potent interaction between THRT and aromatase inhibitors was noted in the second patient cohort. Using in vivo and in vitro models, TH administration enhanced estrogen and TH associated gene expression and proliferation, nuclear co-localization of ER and THR, as well as activation of genes used clinically to predict tumor aggression in SR+ BC including the IGF-IR, WNT, and TGFβ pathways.
CONCLUSIONS: We show clinically significant adverse interactions between THRT, estrogenic and oncogenic signaling in SR+ LN- BC patients.
EXPERIMENTAL DESIGN: Observational studies of lymph node-negative (LN-) BC patients (n= 820 and n=160) were performed to test interactions between THRT and clinical, histologic, outcome and treatment variables. Differences between the two cohorts include but are not limited to patient numbers, decades of treatment, duration of follow-up/treatment, tumor sizes, incidence, type and dose/regimen of anti-hormonal and/or chemotherapeutic agents. In vivo and vitro models, in silico databases and molecular methods were used to study interactions and define mechanisms underlying THRT effects.
RESULTS: THRT significantly and independently reduced disease-free and BC specific overall survival of only the steroid receptor (SR) positive (as compared to SR negative) node-negative patients in both long-term observational studies. SR+ LN- BC patients who received THRT and tamoxifen experienced the shortest survival of all treatment groups. A less potent interaction between THRT and aromatase inhibitors was noted in the second patient cohort. Using in vivo and in vitro models, TH administration enhanced estrogen and TH associated gene expression and proliferation, nuclear co-localization of ER and THR, as well as activation of genes used clinically to predict tumor aggression in SR+ BC including the IGF-IR, WNT, and TGFβ pathways.
CONCLUSIONS: We show clinically significant adverse interactions between THRT, estrogenic and oncogenic signaling in SR+ LN- BC patients.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app